Published in J Pharmacol Exp Ther on October 01, 1973
On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A (1977) 3.18
The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest (2012) 2.65
Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol (2010) 2.54
Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol (2007) 2.31
Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res (2013) 1.62
Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol Appl Pharmacol (2013) 1.46
Predicting outcome of paracetamol poisoning by use 14C-aminopyrine breath test. Br Med J (1980) 1.28
Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci U S A (1982) 1.26
Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol (1991) 1.25
Paracetamol, alcohol and the liver. Br J Clin Pharmacol (2000) 1.19
Proteomic approaches to characterize protein modifications: new tools to study the effects of environmental exposures. Environ Health Perspect (2002) 1.14
The role of biotransformation in chemical-induced liver injury. Environ Health Perspect (1976) 0.98
A dog model for acetaminophen-induced fulminant hepatic failure. Gastroenterology (1989) 0.98
Modeling kinetics of subcellular disposition of chemicals. Chem Rev (2009) 0.96
Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production. Toxicol Sci (2012) 0.96
The biochemistry of acetaminophen hepatotoxicity and rescue: a mathematical model. Theor Biol Med Model (2012) 0.94
The role of metabolism in the immunogenicity of drugs: production of antibodies to a horseradish peroxidase generated conjugate paracetamol. Clin Exp Immunol (1985) 0.92
Plasma glutathione S-transferase measurements after paracetamol overdose: evidence for early hepatocellular damage. Gut (1985) 0.91
Irreversible protein binding of [14C]-practolol metabolite(s) to hamster liver microsomes (proceedings). Br J Pharmacol (1977) 0.91
Hepatotoxicity of mild analgesics. Br J Clin Pharmacol (1980) 0.90
Paracetamol. Postgrad Med J (1980) 0.88
Liposome-encapsulated superoxide dismutase prevents liver necrosis induced by acetaminophen. Am J Pathol (1990) 0.88
Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice. Blood (2015) 0.88
Methanol extract of Melastoma malabathricum leaves exerted antioxidant and liver protective activity in rats. BMC Complement Altern Med (2013) 0.86
Novel acetylcysteine regimens for treatment of paracetamol overdose. Ther Adv Drug Saf (2012) 0.86
Proteomic analysis of acetaminophen-induced changes in mitochondrial protein expression using spectral counting. Chem Res Toxicol (2011) 0.85
Protection of rats against the hepatotoxic effect of paracetamol. Br J Exp Pathol (1974) 0.84
The third Lilly Prize Lecture. University of London, January, 1979. The nephrotoxicity and hepatotoxicity of antipyretic analgesics. Br J Clin Pharmacol (1979) 0.82
Comparative evaluation of N-acetylcysteine and N-acetylcysteineamide in acetaminophen-induced hepatotoxicity in human hepatoma HepaRG cells. Exp Biol Med (Maywood) (2014) 0.81
Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) (2015) 0.81
Reactive metabolites of phenacetin and acetaminophen: a review. Environ Health Perspect (1983) 0.81
Direct protection against acetaminophen hepatotoxicity by propylthiouracil. In vivo and in vitro studies in rats and mice. J Clin Invest (1981) 0.80
Outcomes of patients with acetaminophen-associated toxic hepatitis at a far east poison center. Springerplus (2013) 0.80
Understanding a substrate's product regioselectivity in a family of enzymes: a case study of acetaminophen binding in cytochrome P450s. PLoS One (2014) 0.79
S-adenosyl-l-methionine protection of acetaminophen mediated oxidative stress and identification of hepatic 4-hydroxynonenal protein adducts by mass spectrometry. Toxicol Appl Pharmacol (2014) 0.79
Evidence for cellular protein covalent binding derived from styrene metabolite. Chem Biol Interact (2010) 0.78
Hypothyroidism protects rat liver from acetaminophen hepatotoxicity. Dig Dis Sci (1999) 0.77
Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children. Clin Pharmacokinet (1989) 0.77
Xenobiotic and Endobiotic Mediated Interactions Between the Cytochrome P450 System and the Inflammatory Response in the Liver. Adv Pharmacol (2015) 0.76
Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose? Open Access Emerg Med (2011) 0.75
Treatment of acute paracetamol poisoning. Br Med J (1977) 0.75
Protective effect of chlormethiazole, a sedative, against acetaminophen-induced liver injury in mice. Korean J Intern Med (1999) 0.75
Biomonitoring Human Albumin Adducts: The Past, the Present, and the Future. Chem Res Toxicol (2016) 0.75
Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J (1975) 9.18
A simple, sensitive method for the assay of adenyl cyclase. J Pharmacol Exp Ther (1968) 8.05
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology (1974) 4.32
A randomised trial of home-versus-hospital management for patients with suspected myocardial infarction. Lancet (1978) 4.12
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther (1973) 3.89
Interim discharge summaries: how are they best delivered to general practitioners? Br Med J (Clin Res Ed) (1987) 3.64
Menopausal flushing: does oestrogen therapy make sense? Lancet (1976) 3.47
Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry (1995) 3.30
Self-poisoning: management of patients in Nottingham, 1976. Br Med J (1978) 3.24
Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines. J Pharmacol Exp Ther (1966) 2.75
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Accumulation and elimination of poliovirus by the eastern oyster. Am J Epidemiol (1966) 2.58
Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet (1980) 2.53
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol (1997) 2.35
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med (1976) 2.33
Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J (1980) 2.32
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
RNA binding domain of telomerase reverse transcriptase. Mol Cell Biol (2001) 2.27
Effect of a pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature (1965) 2.19
Is nursing any business of doctors? A simple guide to the "nursing process". Br Med J (Clin Res Ed) (1984) 2.17
Early reporting of myocardial infarction: impact of an experiment in patient education. Br Med J (Clin Res Ed) (1982) 2.11
Beta-receptor activity in aorta; variations with age and species. Circ Res (1970) 2.06
Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 2.02
Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci U S A (1971) 2.00
Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia. Br J Obstet Gynaecol (1991) 1.91
Interrelationships of catecholamines with other endocrine systems. Pharmacol Rev (1966) 1.89
Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Br Med J (1967) 1.85
Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet (1985) 1.84
An association between abo blood-group distribution and geographical differences in death-rates. Lancet (1977) 1.81
Effect of dipyridamole on human platelet behaviour. Lancet (1965) 1.79
Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther (1983) 1.79
Interactions of drugs with adrenergic neurons. Pharmacol Rev (1966) 1.76
Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: effect of drug substrates. Mol Pharmacol (1969) 1.76
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol Pharmacol (1976) 1.73
Dexamethasone in acute stroke. Br Med J (1978) 1.73
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Displacement of one drug by another from carrier or receptor sites. Proc R Soc Med (1965) 1.68
Biochemistry of drug oxidation and reduction by enzymes in hepatic endoplasmic reticulum. Adv Pharmacol (1966) 1.68
Is an information booklet for patients leaving hospital helpful and useful? BMJ (1989) 1.68
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
What constitutes evidence on the dietary prevention of coronary heart disease? Cosy beliefs or harsh facts? Int J Cardiol (1984) 1.66
The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res (2000) 1.64
Changes in Michaelis and spectral constants for aniline in hepatic microsomes from phenobarbital-treated rats. Mol Pharmacol (1969) 1.62
Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet (1988) 1.62
The role of the interview in student selection. S Afr Med J (1978) 1.59
Autumn Books: Who needs Clinical Pharmacology? Br Med J (Clin Res Ed) (1984) 1.57
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk. Br Med J (Clin Res Ed) (1982) 1.55
Effect of aggregating agents on the electrophoretic mobility of human platelets. Br Med J (1966) 1.55
The effects of inorganic ions on the storage and uptake of H3-norepinephrine by rat heart slices. J Pharmacol Exp Ther (1969) 1.55
Prevention and diagnosis of venous thrombosis in patients with hip fractures. A survey of current practice. Lancet (1976) 1.52
Blood pressure reduction in elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed) (1981) 1.52
Effect of oestrogens on human platelet behaviour. Lancet (1968) 1.49
Low dose beta blockade in acute stroke ("BEST" trial): an evaluation. Br Med J (Clin Res Ed) (1988) 1.47
The value of phenobarbital in the child who has had a single febrile seizure: a controlled prospective study. Pediatrics (1977) 1.46
Use of isolated perfused organs in hypoxia and ischemia/reperfusion oxidant stress. Methods Enzymol (1990) 1.46
Patients' and general practitioners' satisfaction with information given on discharge from hospital: audit of a new information card. BMJ (1989) 1.45
Studies on the destruction of liver microsomal cytochrome P-450 by carbon tetrachloride administration. Biochem Pharmacol (1968) 1.43
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry (1991) 1.42
Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology (1975) 1.42
Reactive oxygen species during ischemia-reflow injury in isolated perfused rat liver. J Clin Invest (1988) 1.38
Interaction between desipramine, tyramine, and amphetamine at adrenergic neurones. Br J Pharmacol (1968) 1.38
Parent and peer attachment in early adolescent depression. J Abnorm Child Psychol (1990) 1.38
Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science (1976) 1.38
Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging (2000) 1.37
Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology (1995) 1.36
Anticoagulants in coronary heart disease--retrospect and prospect. Lancet (1981) 1.36
Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res (1967) 1.32
Abnormalities in platelet behaviour in acute illnesses. Br Med J (1966) 1.31
Treatment of high blood pressure: should clinical practice be based on results of clinical trials? Br Med J (Clin Res Ed) (1986) 1.31
Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry. Arch Gen Psychiatry (1989) 1.31